Lixte Biotechnology Holdings Inc. (8640)

Overview

Lixte Biotechnology Holdings, Inc. is recognized as a pioneering clinical-stage biopharmaceutical company deeply engrossed in the development of innovative therapies for severe common diseases. The foundation of their research and development strategy lies in the utilization of biomarker technology to pinpoint critical enzyme targets. A significant area of focus for the company is the discovery and development of inhibitors of protein phosphatase 2A (PP2A), a protein crucial in many cellular processes. This focus stems from its potential utility across a wide spectrum of cancer therapies. The company prides itself on its collaborative efforts, having established noteworthy clinical research agreements with esteemed institutions such as the Moffitt Cancer Center and Research Institute Hospital Inc., along with securing license agreements with the National Institute of Health and Moffitt Cancer Center. Moreover, Lixte Biotechnology has embarked on collaboration agreements for conducting clinically driven investigations with the Spanish Sarcoma Group and the Netherlands Cancer Institute along with Oncode Institute, showcasing its commitment to advancing the field of cancer therapy through both independent and collaborative research endeavors. Founded in the year 2005, Lixte Biotechnology Holdings, Inc. is strategically headquartered in Pasadena, California, positioning itself in a vibrant hub of biotechnological innovation and research.

Products and Services

• LB-100

The flagship of Lixte Biotechnology Holdings, Inc.'s product pipeline is LB-100, an innovative inhibitor of protein phosphatase 2A (PP2A). LB-100 stands out for its versatility and efficacy when used in tandem with various cancer therapies. These include cytotoxic agents, X-ray therapy, immune checkpoint blockers, and other contemporary cancer treatments. The development of LB-100 has successfully advanced through a Phase I clinical trial targeting advanced soft tissue carcinoma and small cell lung cancer. Currently, LB-100 is progressing through a Phase II clinical trial, focusing on its efficacy against ovarian clear cell cancer. The progression of LB-100 from early to mid-stage clinical trials underscores Lixte Biotechnology Holdings, Inc.'s dedication to addressing unmet medical needs in the oncology landscape through the exploration of novel therapeutic avenues.